CBER Director Midthun Retiring; Legacy Includes Biosimilar Principles, Avastin Withdrawal

While CBER is often perceived to be as much focused on research as it is on application review, Midthun was central to many key policy debates.

Karen Midthun plans to retire as director of the Center for Biologics Evaluation and Research, leaving FDA about three months to find a replacement.

Midthun, who became acting center director in 2009 and then permanent director in 2010, will leave at the end of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

More from North America